Peter prepares, prosecutes, and manages extensive patent and trademark portfolios on behalf of companies and academic institutions located throughout the United States, Asia, and Europe. His clients include academic and governmental research institutions; Global 1000 manufacturing, chemical, and pharmaceutical companies; emerging and developing biotechnology and small molecule pharmaceutical companies; and medical technology companies.

Peter’s cases involve pharmaceuticals, specialty chemicals, biotechnology, medical devices, and other mechanical and electromechanical innovations, particularly as they relate to the automotive industry. He regularly provides opinions on issues of patent infringement and validity.

Peter has been quoted on intellectual property issues in publications including the New York Times, Bloomberg, the Los Angeles Times, the Boston Globe, American Lawyer, and Boston Business Journal.

Prior to joining the firm, he was a partner in the Boston office of another international law firm, where he served as co-chair of the firm’s patent procurement practice. Peter is also an inventor on US Patent 4,977,173 “Aminomethyl Oxooxazolidinyl Ethenylbenzene Derivatives Useful As Antibacterial Agents,” which covers predecessor development compounds to Pfizer's oxazolidinone antibacterial Zyvox, now in clinical use. Before law school, he pursued graduate studies in chemistry while employed as a synthetic organic chemist in a drug discovery group of E.I. DuPont de Nemours Co., Medical Products Department (later the DuPont Pharmaceutical Company and now merged with Bristol-Myers Squibb).